BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37903943)

  • 1. Cost minimization analysis of subcutaneous trastuzumab versus intravenous biosimilar trastuzumab: policy recommendations for breast cancer treatment in Malaysia.
    Heng JE; Raman S; Wong ZY; Beh VJN
    Daru; 2024 Jun; 32(1):67-76. PubMed ID: 37903943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer.
    Rojas L; Muñiz S; Medina L; Peña J; Acevedo F; Pinto MP; Sanchez C
    PLoS One; 2020; 15(2):e0227961. PubMed ID: 32023267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Costs of intravenous vs. subcutaneous administration of trastuzumab in peruvian patients with HER2-positive breast cancer - An observational analysis of direct and indirect costs].
    Olivera Changra H; Robles Díaz JF
    J Healthc Qual Res; 2022; 37(3):147-154. PubMed ID: 34887227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.
    O'Brien GL; O'Mahony C; Cooke K; Kinneally A; Sinnott SJ; Walshe V; Mulcahy M; Byrne S
    Clin Breast Cancer; 2019 Jun; 19(3):e440-e451. PubMed ID: 30853347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
    Tjalma WAA; Van den Mooter T; Mertens T; Bastiaens V; Huizing MT; Papadimitriou K
    Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():46-51. PubMed ID: 29245056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
    Elsamany S; Elsisi GH; Hassanin F; Jafal M
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):511-518. PubMed ID: 33275459
    [No Abstract]   [Full Text] [Related]  

  • 7. White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example.
    Jackisch C; Manevy F; Frank S; Roberts N; Shafrin J
    Adv Ther; 2022 Feb; 39(2):833-844. PubMed ID: 34988876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.
    Lopez-Vivanco G; Salvador J; Diez R; López D; De Salas-Cansado M; Navarro B; De la Haba-Rodríguez J
    Clin Transl Oncol; 2017 Dec; 19(12):1454-1461. PubMed ID: 28577152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.
    North RT; Harvey VJ; Cox LC; Ryan SN
    Clinicoecon Outcomes Res; 2015; 7():423-30. PubMed ID: 26251623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting.
    Olofsson S; Norrlid H; Karlsson E; Wilking U; Ragnarson Tennvall G
    Breast; 2016 Oct; 29():140-6. PubMed ID: 27498127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer.
    McBride A; MacDonald K; Fuentes-Alburo A; Abraham I
    J Med Econ; 2021; 24(1):743-756. PubMed ID: 34003067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.
    Franken MG; Kanters TA; Coenen JL; de Jong P; Koene HR; Lugtenburg PJ; Jager A; Uyl-de Groot CA
    Anticancer Drugs; 2018 Sep; 29(8):791-801. PubMed ID: 29846248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study.
    Simoens S; Vulto AG; Dylst P
    Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34064559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden.
    Hedayati E; Fracheboud L; Srikant V; Greber D; Wallberg S; Linder Stragliotto C
    PLoS One; 2019; 14(2):e0211783. PubMed ID: 30716137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
    Lazaro Cebas A; Cortijo Cascajares S; Pablos Bravo S; Del Puy Goyache Goñi M; Gonzalez Monterrubio G; Perez Cardenas MD; Ferrari Piquero JM
    J BUON; 2017; 22(2):334-339. PubMed ID: 28534353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients.
    Farolfi A; Silimbani P; Gallegati D; Petracci E; Schirone A; Altini M; Masini C
    Oncotarget; 2017 Oct; 8(46):81343-81349. PubMed ID: 29113393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting.
    Barat EC; Arrii MLE; Soubieux-Bourbon A; Daouphars M; Varin R; Tilleul PR
    Breast; 2023 Dec; 72():103588. PubMed ID: 37857129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
    Altini M; Gentili N; Balzi W; Musuraca G; Maltoni R; Masini C; Galardi F; Bertoni L; Massa I
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):503-509. PubMed ID: 32403958
    [No Abstract]   [Full Text] [Related]  

  • 19. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
    Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
    Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients.
    Delgado Sánchez O; Gutiérrez A; do Pazo F; Ginés J; Martorell C; Boyeras B; Bento L; Garcia-Recio M; Sampol A
    Clinicoecon Outcomes Res; 2019; 11():695-701. PubMed ID: 31819561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.